Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

629
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
629
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

481
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
481
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

575
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
575

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Leaf bleaching is associated with extensive transcriptional reprogramming in avocado trees with sunblotch disease.

Virology·2026
Same author

Real-life outcomes of the PAUL® Glaucoma Implant with ripcord in refractory glaucoma.

Journal francais d'ophtalmologie·2026
Same author

[Phuc LeHoang: A giant in ophthalmology].

Journal francais d'ophtalmologie·2025
Same author

[Recommendations for rational use of new anti-VEGF biologicals].

Journal francais d'ophtalmologie·2025
Same author

Practical implementation of automated insulin delivery systems in 2025: A French position statement update.

Diabetes & metabolism·2025
Same author

Lack of efficacy of sofosbuvir in Human Pegivirus associated neurological disorders.

Revue neurologique·2025
Same journal

[Abdominal pain, fever and arthralgia in a 49-year-old woman].

La Revue de medecine interne·2026
Same journal

[Cardiorespiratory functional disorders: A transnosologic approach].

La Revue de medecine interne·2026
Same journal

[Diagnostic evaluation for suspected polycythemia].

La Revue de medecine interne·2026
Same journal

Heart involvements in systemic sclerosis beyond pulmonary hypertension: From conduction, rhythm and function defects to coronary artery disease.

La Revue de medecine interne·2026
Same journal

[Acute intermittent porphyria: When diagnostic errance jeopardizes patient health].

La Revue de medecine interne·2026
Same journal

Autosomal dominant polycystic kidney disease: Current perspectives in 2026.

La Revue de medecine interne·2026
See all related articles

Related Experiment Video

Updated: Jul 24, 2025

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

2.7K

Behçet's disease uveitis.

M Joubert1, A-C Desbois1, F Domont1

  • 1Department of Internal Medicine and Clinical Immunology, centre de référence des maladies auto-immunes systémiques rares, centre de référence des maladies auto-inflammatoires et de l'amylose inflammatoire, Sorbonne universités, Pitié-Salpêtrière University Hospital, AP-HP, Inserm, UMR_S 959, 83, boulevard de l'Hôpital, 75013 Paris, France.

La Revue De Medecine Interne
|July 6, 2023
PubMed
Summary
This summary is machine-generated.

Behçet

Keywords:
Agents anti-TNFαAnti-TNFα agentsBehçet's diseaseBiotherapiesBiothérapiesMaladie de BehçetUveitisUvéiteVasculariteVasculitis

More Related Videos

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

4.9K
Iris Fixation via External Pentagram Suturing
05:22

Iris Fixation via External Pentagram Suturing

Published on: May 5, 2022

1.4K

Related Experiment Videos

Last Updated: Jul 24, 2025

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

2.7K
Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

4.9K
Iris Fixation via External Pentagram Suturing
05:22

Iris Fixation via External Pentagram Suturing

Published on: May 5, 2022

1.4K

Area of Science:

  • Ophthalmology
  • Rheumatology
  • Immunology

Background:

  • Behçet's disease (BD) frequently causes uveitis, a significant cause of morbidity, often appearing between ages 20-30.
  • Ocular involvement in BD includes anterior, posterior, or panuveitis, with panuveitis being the most common presentation, particularly in men.
  • Uveitis can be an initial symptom of BD or manifest years later, carrying a 10-15% risk of blindness within 5 years.

Purpose of the Study:

  • To provide an updated review on the pathogenesis and diagnostic approaches for uveitis in Behçet's disease.
  • To identify factors associated with relapse in Behçet's disease uveitis.
  • To outline current therapeutic strategies, including the impact of biologic therapies, for managing Behçet's disease uveitis.

Main Methods:

  • Review of existing literature on Behçet's disease uveitis.
  • Analysis of diagnostic criteria and ophthalmological features.
  • Evaluation of treatment outcomes, focusing on biologic therapies.

Main Results:

  • Behçet's disease uveitis presents unique ophthalmological characteristics.
  • Biologic therapies have significantly improved the management of intraocular inflammation in BD.
  • Understanding relapse factors is crucial for effective long-term management.

Conclusions:

  • Effective management of Behçet's disease uveitis requires rapid control of inflammation, prevention of recurrence, and vision preservation.
  • Biologic agents represent a major advancement in treating this condition.
  • Further research into pathogenesis and relapse predictors can optimize therapeutic strategies.